The mesothelial origin of carcinoma associated-fibroblasts in peritoneal metastasis

Cancers

Volumn 7, Issue 4, 2015, Pages 1994-2011

  Rynne Vidal, Angela ^a   Jiménez Heffernan, José Antonio ^b,c   Fernández Chacón, Concepción ^c   López Cabrera, Manuel ^a   Sandoval, Pilar ^a  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^b Instituto de Investigación Sanitaria del Hospital Universitario de La Princesa   (Spain)

^c Hospital de la Zarzuela   (Spain)

Author keywords

Carcinoma associated fibroblasts; Mesothelial cells; Mesothelial to mesenchymal transition; Peritoneal metastasis; Therapeutic strategies

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; CALVASCULIN; GELATINASE A; GELATINASE B; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; OSTEOGENIC PROTEIN 1; SCATTER FACTOR; SEPRASE; SMALL INTERFERING RNA; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; UROKINASE; VASCULOTROPIN;

ARTICLE; CARCINOGENESIS; CARCINOMA ASSOCIATED FIBROBLAST; CELL PROLIFERATION; CELL TRANSFORMATION; ENDOTHELIUM CELL; EPIGENETICS; EPITHELIAL MESENCHYMAL TRANSITION; EXTRACELLULAR MATRIX; FIBROBLAST; HUMAN; IMMUNOHISTOCHEMISTRY; MESOTHELIAL TO MESENCHYMAL TRANSITION; MESOTHELIUM CELL; NUCLEAR REPROGRAMMING; PERITONEAL CAVITY; PERITONEUM ADHESION; PERITONEUM METASTASIS; PROTEIN EXPRESSION; SCANNING ELECTRON MICROSCOPY; STROMA; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION;

EID: 84942917302     PISSN: None     EISSN: 20726694     Source Type: Journal    
DOI: 10.3390/cancers7040872     Document Type: Article

References (164)

1. De Cuba, E.M.; Kwakman, R.; van Egmond, M.; Bosch, L.J.; Bonjer, H.J.; Meijer, G.A.; te Velde, E.A. Understanding molecular mechanisms in peritoneal dissemination of colorectal cancer: Future possibilities for personalised treatment by use of biomarkers. Virchows Arch. 2012, 461, 231–243. [CrossRef] [PubMed]
2. Tan, D.S.; Agarwal, R.; Kaye, S.B. Mechanisms of transcoelomic metastasis in ovarian cancer. Lancet Oncol. 2006, 7, 925–934. [CrossRef]
3. Sohaib, S.A.; Houghton, S.L.; Meroni, R.; Rockall, A.G.; Blake, P.; Reznek, R.H. Recurrent endometrial cancer: Patterns of recurrent disease and assessment of prognosis. Clin. Radiol. 2007, 62, 28–34. [CrossRef] [PubMed]
4. Koppe, M.J.; Boerman, O.C.; Oyen, W.J.; Bleichrodt, R.P. Peritoneal carcinomatosis of colorectal origin: Incidence and current treatment strategies. Ann. Surg. 2006, 243, 212–222. [CrossRef] [PubMed]
5. Montori, G.; Coccolini, F.; Ceresoli, M.; Catena, F.; Colaianni, N.; Poletti, E.; Ansaloni, L. The treatment of peritoneal carcinomatosis in advanced gastric cancer: State of the art. Int. J. Surg. Oncol. 2014, 2014, 912418. [CrossRef] [PubMed]
6. Glehen, O.; Cotte, E.; Brigand, C.; Arvieux, C.; Sayag-Beaujard, A.C.; Gilly, F.N. Nouveautés thérapeutiques dans la prise en charge des carcinoses péritonéales d'origine digestive: Chirurgie de cytoréduction et chimiothérapie intrapéritonéale. [Therapeutic innovations in the management of peritoneal carcinomatosis from digestive origin: Cytoreductive surgery and intraperitoneal chemotherapy]. Rev. Med. Interne 2006, 27, 382–391. [PubMed]
7. Bakrin, N.; Classe, J.M.; Pomel, C.; Gouy, S.; Chene, G.; Glehen, O. Hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer. J. Visc. Surg. 2014, 151, 347–353. [CrossRef]
8. Glockzin, G.; Schlitt, H.J.; Piso, P. Peritoneal carcinomatosis: Patients selection, perioperative complications and quality of life related to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. World J. Surg. Oncol. 2009, 7, 5. [CrossRef] [PubMed]
9. Sandoval, P.; Jiménez-Heffernan, J.A.; Rynne-Vidal, A.; Pérez-Lozano, M.L.; Gilsanz, A.; Ruiz-Carpio, V.; Reyes, R.; García-Bordas, J.; Stamatakis, K.; Dotor, J. et al. Carcinoma-associated fibroblasts derive from mesothelial cells via mesothelial to mesenchymal transition in peritoneal metastasis. J. Pathol. 2013, 231, 517–531. [CrossRef] [PubMed]
10. Chambers, A.F.; Groom, A.C.; MacDonald, I.C. Dissemination and growth of cancer cells in metastatic sites. Nat. Rev. Cancer 2002, 2, 563–572. [CrossRef] [PubMed]
11. Mendoza, M.; Khanna, C. Revisiting the seed and soil in cancer metastasis. Int. J. Biochem. Cell Biol. 2009, 41, 1452–1462. [CrossRef] [PubMed]
12. Mathot, L.; Stenninger, J. Behavior of seeds and soil in the mechanism of metastasis: A deeper understanding. Cancer Sci. 2012, 103, 626–631. [CrossRef] [PubMed]
13. Di Paolo, N.; Sacchi, G. Atlas of peritoneal histology. Perit. Dial. Int. 2000, 20, S5–S96. [PubMed]
14. Hanahan, D.; Weinberg, R.A. Hallmarks of cancer: The next generation. Cell 2011, 144, 646–674. [CrossRef] [PubMed]
15. Bhome, R.; Bullock, M.D.; Al Saihati, H.A.; Goh, R.W.; Primrose, J.N.; Sayan, A.E.; Mirnezami, A.H. A top-down view of the tumor microenvironment: Structure, cells and signaling. Front. Cell Dev. Biol. 2015, 3, 33. [CrossRef] [PubMed]
16. Kojima, M.; Higuchi, Y.; Yokota, M.; Ishii, G.; Saito, N.; Aoyagi, K.; Sasaki, H.; Ochiai, A. Human subperitoneal fibroblast and cancer cell interaction creates microenvironment that enhances tumor progression and metastasis. PLoS ONE 2014, 9, e88018. [CrossRef] [PubMed]
17. Jimenez-Heffernan, J.A.; Aguilera, A.; Aroeira, L.S.; Lara-Pezzi, E.; Bajo, M.A.; del Peso, G.; Ramirez, M.; Gamallo, C.; Sanchez-Tomero, J.A.; Alvarez, V. et al. Immunohistochemical characterization of fibroblast subpopulations in normal peritoneal tissue and in peritoneal dialysis-induced fibrosis. Virchows Arch. 2004, 444, 247–256. [CrossRef] [PubMed]
18. Chegini, N. TGF-beta system: The principal profibrotic mediator of peritoneal adhesion formation. Semin. Reprod. Med. 2008, 26, 298–312. [CrossRef] [PubMed]
19. Orimo, A.; Weinberg, R.A. Stromal fibroblasts in cancer: A novel tumor-promoting cell type. Cell Cycle 2006, 5, 1597–1601. [CrossRef] [PubMed]
20. Desmoulière, A.; Gabbiani, G. Modulation of fibroblastic cytoskeletal features during pathological situations: The role of extracellular matrix and cytokines. Cell Motil. Cytoskeleton 1994, 29, 195–203. [CrossRef] [PubMed]
21. Desmoulière, A.; Geinoz, A.; Gabbiani, F.; Gabbiani, G. Transforming growth factor-beta1 induces a-smoothmuscle actin expression in granulation tissue myofibroblasts and in quiescent and growing cultured fibroblasts. J. Cell Biol. 1993, 122, 103–111. [CrossRef] [PubMed]
22. Lazard, D.; Sastre, X.; Frid, M.G.; Glukhova, M.A.; Thiery, J.-P.; Koteliansky, V.E. Expression of smooth muscle-specific proteins in myoepithelium and stromal myofibroblasts ofnormal and malignant human breast tissue. Proc. Natl. Acad. Sci. USA 1993, 90, 999–1003. [CrossRef] [PubMed]
23. Calon, A.; Espinet, E.; Palomo-Ponce, S.; Tauriello, D.V.F.; Iglesias, M.; Céspedes, M.V.; Sevillano, M.; Nadal, C.; Jung, P.; Zhang, X.H.F. et al. Dependency of Colorectal Cancer on a TGF-_-Driven Program in Stromal Cells for Metastasis Initiation. Cancer Cell 2012, 22, 571–584. [CrossRef] [PubMed]
24. Wikberg, M.L.; Edin, S.; Lundberg, I.V.; van Guelpen, B.; Dahlin, A.M.; Rutegard, J.; Stenling, R.; Oberg, A.; Palmqvist, R. High intratumoral expression of fibroblast activation protein (FAP) in colon cancer is associated with poorer patient prognosis. Tumor Biol. 2013, 34, 1013–1020. [CrossRef] [PubMed]
25. Strutz, F.; Okada, H.; Lo, C.W.; Danoff, T.; Carone, R.L.; Tomaszewski, J.E.; Neilson, E.G. Identification and characterization of a fibroblast marker: FSP1. J. Cell Biol. 1995, 130, 393–405. [CrossRef] [PubMed]
26. Polanska, U.M.; Orimo, A. Carcinoma-associated fibroblasts: Non-neoplastic tumor-promoting mesenchymal cells. J. Cell. Physiol. 2013, 228, 1651–1657. [CrossRef] [PubMed]
27. Wels, J.; Kaplan, R.N.; Rafii, S.; Lyden, D. Migratory neighbors and distant invaders: Tumor-associated niche cells. Genes Dev. 2008, 22, 559–574. [CrossRef] [PubMed]
28. Bhowmick, N.A.; Neilson, E.G.; Moses, H.L. Stromal fibroblasts in cancer initiation and progression. Nature 2004, 432, 332–337. [CrossRef] [PubMed]
29. Cirri, P.; Chiarugi, P. Cancer-associated-fibroblasts and tumor cells: A diabolic liaison driving cancer progression. Cancer Metastasis Rev. 2012, 31, 195–208. [CrossRef] [PubMed]
30. Desmoulière, A.; Guyot, C.; Gabbiani, G. The stroma reaction myofibroblast: A key player in the control of tumor cell behavior. Int. J. Dev. Biol. 2004, 48, 509–517. [CrossRef] [PubMed]
31. Kalluri, R.; Zeisberg, M. Fibroblasts in cancer. Nat. Rev. Cancer 2006, 6, 392–401. [CrossRef] [PubMed]
32. Lopez-Novoa, J.M.; Nieto, M.A. Inflammation and EMT: An alliance towards organ fibrosis and cancer progression. EMBO Mol. Med. 2009, 1, 303–314. [CrossRef] [PubMed]
33. Potenta, S.; Zeisberg, E.; Kalluri, R. The role of endothelial-to-mesenchymal transition in cancer progression. Br. J. Cancer 2008, 99, 1375–1379. [CrossRef] [PubMed]
34. Zeisberg, E.M.; Potenta, S.E.; Sugimoto, H.; Zeisberg, M.; Kalluri, R. Fibroblasts in kidney fibrosis emerge via endothelial-to-mesenchymal transition. J. Am. Soc. Nephrol. 2008, 19, 2282–2287. [CrossRef] [PubMed]
35. Yanez-Mo, M.; Lara-Pezzi, E.; Selgas, R.; Ramirez-Huesca, M.; Dominguez-Jimenez, C.; Jimenez-Heffernan, J.A.; Aguilera, A.; Sanchez-Tomero, J.A.; Bajo, M.A.; Alvarez, V. et al. Peritoneal dialysis and epithelial-to-mesenchymal transition of mesothelial cells. N. Engl. J. Med. 2003, 348, 403–413. [CrossRef] [PubMed]
36. Karki, S.; Surolia, R.; Hock, T.D.; Guroji, P.; Zolak, J.S.; Duggal, R.; Ye, T.; Thannickal, V.J.; Antony, V.B. Wilms’ tumor 1 (Wt1) regulates pleural mesothelial cell plasticity and transition into myofibroblasts in idiopathic pulmonary fibrosis. FASEB J. 2014, 28, 1122–1131. [CrossRef] [PubMed]
37. Li, Y.; Wang, J.; Asahina, K. Mesothelial cells give rise to hepatic stellate cells and myofibroblasts via mesothelial-mesenchymal transition in liver injury. Proc. Natl. Acad. Sci. USA 2013, 110, 2324–2329. [CrossRef] [PubMed]
38. Ruiz-Villalba, A.; Simón, A.M.; Pogontke, C.; Castillo, M.I.; Abizanda, G.; Pelacho, B.; Sánchez-Domínguez, R.; Segovia, J.C.; Prósper, F.; Pérez-Pomares, J.M. Interacting resident epicardium-derived fibroblasts and recruited bone marrow cells form myocardial infarction scar. J. Am. Coll. Cardiol. 2015, 65, 2057–2066. [CrossRef] [PubMed]
39. Deb, A.; Ubil, E. Cardiac fibroblast in development and wound healing. J. Mol. Cell. Cardiol. 2014, 70, 47–55. [CrossRef] [PubMed]
40. Miao, Z.-F.; Zhao, T.-T.; Wang, Z.-N.; Miao, F.; Xu, Y.-Y.; Mao, X.-Y.; Gao, J.; Xu, H.-M. Tumor-associated mesothelial cells are negative prognostic factors in gastric cancer and promote peritoneal dissemination of adherent gastric cancer cells by chemotaxis. Tumor Biol. 2014, 35, 6105–6111. [CrossRef] [PubMed]
41. López-Cabrera, M. Mesenchymal conversion of mesothelial cells is a key event in the pathophysiology of the peritoneum during peritoneal dialysis. Adv. Med. 2014, 2014, 1–17. [CrossRef]
42. Kalluri, R.; Weinberg, R.A. The basics of epithelial-mesenchymal transition. J. Clin. Investig. 2009, 119, 1420–1428. [CrossRef] [PubMed]
43. Devuyst, O.; Margetts, P.J.; Topley, N. The pathophysiology of the peritoneal membrane. J. Am. Soc. Nephrol. 2010, 21, 1077–1085. [CrossRef] [PubMed]
44. Margetts, P.J.; Bonniaud, P. Basic mechanisms and clinical implications of peritoneal fibrosis. Perit. Dial. Int. 2003, 23, 530–541. [PubMed]
45. Aroeira, L.S.; Aguilera, A.; Sanchez-Tomero, J.A.; Bajo, M.A.; del Peso, G.; Jimenez-Heffernan, J.A.; Selgas, R.; Lopez Cabrera, M. Epithelial to mesenchymal transition and peritoneal membrane failure in peritoneal dialysis patients: Pathologic significance and potential therapeutic interventions. J. Am. Soc. Nephrol. 2007, 18, 2004–2013. [CrossRef] [PubMed]
46. Aguilera, A.; Yanez-Mo, M.; Selgas, R.; Sanchez-Madrid, F.; Lopez Cabrera, M. Epithelial to mesenchymal transition as a triggering factor of peritoneal membrane fibrosis and angiogenesis in peritoneal dialysis patients. Curr. Opin. Investig. Drugs 2005, 6, 262–268. [PubMed]
47. Ayantunde, A.A.; Parsons, S.L. Pattern and prognostic factors in patients with malignant ascites: A retrospective study. Ann. Oncol. 2007, 18, 945–949. [CrossRef] [PubMed]
48. Parsons, S.L.; Lang, M.W.; Steele, R.J. Malignant ascites: A 2-year review from a teaching hospital. Eur. J. Surg. Oncol. 1996, 22, 237–239. [CrossRef]
49. Ayhan, A.; Gultekin, M.; Taskiran, C.; Dursun, P.; Firat, P.; Bozdag, G.; Celik, N.Y.; Yuce, K. Ascites and epithelial ovarian cancers: A reappraisal with respect to different aspects. Int. J. Gynecol. Cancer 2007, 17, 68–75. [CrossRef] [PubMed]
50. Sheid, B. Angiogenic effects of macrophages isolated from ascitic fluid aspirated from women with advanced ovarian cancer. Cancer Lett. 1992, 62, 153–158. [CrossRef]
51. Milliken, D.; Scotton, C.; Raju, S.; Balkwill, F.; Wilson, J. Analysis of chemokines and chemokine receptor expression in ovarian cancer ascites. Clin. Cancer Res. 2002, 8, 1108–1114. [PubMed]
52. Choi, D.-S.; Park, J.O.; Jang, S.C.; Yoon, Y.J.; Jung, J.W.; Choi, D.-Y.; Kim, J.-W.; Kang, J.S.; Park, J.; Hwang, D. et al. Proteomic analysis of microvesicles derived from human colorectal cancer ascites. Proteomics 2011, 11, 2745–2751.
53. Graves, L.E.; Ariztia, E.V.; Navari, J.R.; Matzel, H.J.; Stack, M.S.; Fishman, D.A. Proinvasive properties of ovarian cancer ascites-derived membrane vesicles. Cancer Res. 2004, 64, 7045–7049. [CrossRef] [PubMed]
54. Matte, I.; Lane, D.; Laplante, C.; Rancourt, C.; Piché, A. Profiling of cytokines in human epithelial ovarian cancer ascites. Am. J. Cancer Res. 2012, 2, 566–580. [PubMed]
55. Matte, I.; Lane, D.; Laplante, C.; Garde-Granger, P.; Rancourt, C.; Piché, A. Ovarian cancer ascites enhance the migration of patient-derived peritoneal mesothelial cells viacMet pathway through HGF-dependent and-independent mechanisms. Int. J. Cancer 2014, 137, 289–298. [CrossRef] [PubMed]
56. Sowter, H.M.; Corps, A.N.; Smith, S.K. Hepatocyte growth factor (HGF) in ovarian epithelial tumor fluids stimulates the migration of ovarian carcinoma cells. Int. J. Cancer 1999, 83, 476–480. [CrossRef]
57. Nash, M.A.; Lenzi, R.; Edwards, C.L.; Kavanagh, J.J.; Kudelka, A.P.; Verschraegen, C.F.; Platsoucas, C.D.; Freedman, R.S. Differential expression of cytokine transcripts in human epithelial ovarian carcinoma by solid tumor specimens, peritoneal exudate cells containing tumor, tumor-infiltrating lymphocyte (TIL)-derived T cell lines and established tumor cell lines. Clin. Exp. Immunol. 1998, 112, 172–180. [CrossRef] [PubMed]
58. Stadlmann, S.; Amberger, A.; Pollheimer, J.; Gastl, G.; Offner, F.A.; Margreiter, R.; Zeimet, A.G. Ovarian carcinoma cells and IL-1beta-activated human peritoneal mesothelial cells are possible sources of vascular endothelial growth factor in inflammatory and malignant peritoneal effusions. Gynecol. Oncol. 2005, 97, 784–789. [CrossRef] [PubMed]
59. Manenti, L.; Paganoni, P.; Floriani, I.; Landoni, F.; Torri, V.; Buda, A.; Taraboletti, G.; Labianca, R.; Belotti, D.; Giavazzi, R. Expression levels of vascular endothelial growth factor, matrix metalloproteinases 2 and 9 and tissue inhibitor of metalloproteinases 1 and 2 in the plasma of patients with ovarian carcinoma. Eur. J. Cancer 2003, 39, 1948–1956. [CrossRef]
60. Santin, A.D.; Bellone, S.; Ravaggi, A.; Roman, J.; Smith, C.V.; Pecorelli, S.; Cannon, M.J.; Parham, G.P. Increased levels of interleukin-10 and transforming growth factor-beta in the plasma and ascitic fluid of patients with advanced ovarian cancer. BJOG 2001, 108, 804–808. [CrossRef] [PubMed]
61. Moradi, M.M.; Carson, L.F.; Twiggs, L.B.; Weinberg, J.B.; Haney, A.F.; Ramakrishnan, S. Serum and ascitic fluid levels of interleukin-1, interleukin-6, and tumor necrosis factor-alpha in patients with ovarian epithelial cancer. Cancer 1993, 72, 2433–2440. [CrossRef]
62. Giuntoli, R.L.; Webb, T.J.; Zoso, A.; Rogers, O.; Diaz-Montes, T.P.; Bristow, R.E.; Oelke, M. Ovarian cancer-associated ascites demonstrates altered immune environment: Implications for antitumor immunity. Anticancer Res. 2009, 29, 2875–2884. [PubMed]
63. Masunaga, Y.; Muto, S.; Asakura, S.; Akimoto, T.; Homma, S.; Kusano, E.; Asano, Y. Ascites from patients with encapsulating peritoneal sclerosis augments NIH/3T3 fibroblast proliferation. Ther. Apher. Dial. 2003, 7, 486–493. [CrossRef] [PubMed]
64. Fredj, S.; Bescond, J.; Louault, C.; Delwail, A.; Lecron, J.-C.; Potreau, D. Role of interleukin-6 in cardiomyocyte/cardiac fibroblast interactions during myocyte hypertrophy and fibroblast proliferation. J. Cell. Physiol. 2005, 204, 428–436. [CrossRef] [PubMed]
65. Demir, A.Y.; Groothuis, P.G.; Dunselman, G.A.J.; Schurgers, L.; Evers, J.L.H.; de Goeij, A.F.P.M. Molecular characterization of soluble factors from human menstrual effluent that induce epithelial to mesenchymal transitions in mesothelial cells. Cell Tissue Res. 2005, 322, 299–311. [CrossRef] [PubMed]
66. Freedman, R.S.; Deavers, M.; Liu, J.; Wang, E. Peritoneal inflammation—A microenvironment for Epithelial Ovarian Cancer (EOC). J. Transl. Med. 2004, 2, 23. [CrossRef] [PubMed]
67. Kolomeyevskaya, N.; Eng, K.H.; Khan, A.N.H.; Grzankowski, K.S.; Singel, K.L.; Moysich, K.; Segal, B.H. Cytokine profiling of ascites at primary surgery identifies an interaction of tumor necrosis factor-_ and interleukin-6 in predicting reduced progression-free survival in epithelial ovarian cancer. Gynecol. Oncol. 2015, 138, 352–357. [CrossRef] [PubMed]
68. Matte, I.; Lane, D.; Bachvarov, D.; Rancourt, C.; Piche, A. Role of malignant ascites on human mesothelial cells and their gene expression profiles. BMC Cancer 2014, 14, 288. [CrossRef] [PubMed]
69. Lane, D.; Matte, I.; Rancourt, C.; Piché, A. Prognostic significance of IL-6 and IL-8 ascites levels in ovarian cancer patients. BMC Cancer 2011, 11, 210. [CrossRef] [PubMed]
70. Ono, Y.J.; Hayashi, M.; Tanabe, A.; Hayashi, A.; Kanemura, M.; Terai, Y.; Ohmichi, M. Estradiol-mediated hepatocyte growth factor is involved in the implantation of endometriotic cells via the mesothelial-to-mesenchymal transition in the peritoneum. Am. J. Physiol. Endocrinol. Metab. 2015, 308, E950–E959. [CrossRef] [PubMed]
71. Nakamura, M.; Ono, Y.J.; Kanemura, M.; Tanaka, T.; Hayashi, M.; Terai, Y.; Ohmichi, M. Hepatocyte growth factor secreted by ovarian cancer cells stimulates peritoneal implantation via the mesothelial-mesenchymal transition of the peritoneum. Gynecol. Oncol. 2015. [CrossRef] [PubMed]
72. Thibault, B.; Castells, M.; Delord, J.P.; Couderc, B. Ovarian cancer microenvironment: Implications for cancer dissemination and chemoresistance acquisition. Cancer Metastasis Rev. 2014, 33, 17–39. [CrossRef] [PubMed]
73. Elliott, R.L. Role of transforming growth factor beta in human cancer. J. Clin. Oncol. 2005, 23, 2078–2093. [CrossRef] [PubMed]
74. Loureiro, J.; Aguilera, A.; Selgas, R.; Sandoval, P.; Albar-Vizcaino, P.; Pérez-Lozano, M.L.; Ruiz-Carpio, V.; Majano, P.L.; Lamas, S.; Rodriguez-Pascual, F. et al. Blocking TGF-1 protects the peritoneal membrane from dialysate-induced damage. J. Am. Soc. Nephrol. 2011, 22, 1682–1695. [CrossRef] [PubMed]
75. Yamamura, S.; Matsumura, N.; Mandai, M.; Huang, Z.; Oura, T.; Baba, T.; Hamanishi, J.; Yamaguchi, K.; Kang, H.S.; Okamoto, T. et al. The activated transforming growth factor-beta signaling pathway in peritoneal metastases is a potential therapeutic target in ovarian cancer. Int. J. Cancer 2011, 130, 20–28. [CrossRef] [PubMed]
76. Miao, Z.-F.; Zhao, T.-T.; Wang, Z.-N.; Miao, F.; Xu, Y.-Y.; Mao, X.-Y.; Gao, J.; Wu, J.-H.; Liu, X.-Y.; You, Y. et al. Transforming growth factor-beta1 signaling blockade attenuates gastric cancer cell-induced peritoneal mesothelial cell fibrosis and alleviates peritoneal dissemination both in vitro and in vivo. Tumor Biol. 2013, 35, 3575–3583. [CrossRef] [PubMed]
77. Théry, C.; Zitvogel, L.; Amigorena, S. Exosomes: Composition, biogenesis and function. Nat. Rev. Immunol. 2002, 2, 569–579. [PubMed]
78. Peng, P.; Yan, Y.; Keng, S. Exosomes in the ascites of ovarian cancer patients: Origin and effects on anti-tumor immunity. Oncol. Rep. 2011, 25, 749–762. [PubMed]
79. Cappellesso, R.; Tinazzi, A.; Giurici, T.; Simonato, F.; Guzzardo, V.; Ventura, L.; Crescenzi, M.; Chiarelli, S.; Fassina, A. Programmed cell death 4 and microRNA 21 inverse expression is maintained in cells and exosomes from ovarian serous carcinoma effusions. Cancer Cytopathol. 2014, 122, 685–693. [CrossRef] [PubMed]
80. Tokuhisa, M.; Ichikawa, Y.; Kosaka, N.; Ochiya, T.; Yashiro, M.; Hirakawa, K.; Kosaka, T.; Makino, H.; Akiyama, H.; Kunisaki, C. et al. Exosomal miRNAs from peritoneum lavage fluid as potential prognostic biomarkers of peritoneal metastasis in gastric cancer. PLoS ONE 2015, 10, e0130472. [CrossRef] [PubMed]
81. Vaksman, O.; Trope, C.; Davidson, B.; Reich, R. Exosome-derived miRNAs and ovarian carcinoma progression. Carcinogenesis 2014, 35, 2113–2120. [CrossRef] [PubMed]
82. Selcuklu, S.D.; Donoghue, M.T.A.; Spillane, C. miR-21 as a key regulator of oncogenic processes. Biochem. Soc. Trans. 2009, 37, 918–925. [CrossRef] [PubMed]
83. Na, D.; Lv, Z.D.; Liu, F.N.; Xu, Y.; Jiang, C.G.; Sun, Z.; Miao, Z.F.; Li, F.; Xu, H.M. Transforming growth factor beta1 produced in autocrine/paracrine manner affects the morphology and function of mesothelial cells and promotes peritoneal carcinomatosis. Int. J. Mol. Med. 2010, 26, 325–332. [PubMed]
84. Heath, R.M.; Jayne, D.G.; O’Leary, R.; Morrison, E.E.; Guillou, P.J. Tumor-induced apoptosis in human mesothelial cells: A mechanism of peritoneal invasion by Fas Ligand/Fas interaction. Br. J. Cancer 2004, 90, 1437–1442. [CrossRef] [PubMed]
85. Burleson, K.M.; Hansen, L.K.; Skubitz, A.P. Ovarian carcinoma spheroids disaggregate on type I collagen and invade live human mesothelial cell monolayers. Clin. Exp. Metastasis 2004, 21, 685–697. [CrossRef] [PubMed]
86. Iwanicki, M.P.; Davidowitz, R.A.; Ng, M.R.; Besser, A.; Muranen, T.; Merritt, M.; Danuser, G.; Ince, T.; Brugge, J.S. Ovarian cancer spheroids use myosin-generated force to clear the mesothelium. Cancer Discov. 2011, 1, 144–157. [CrossRef] [PubMed]
87. Davidowitz, R.A.; Selfors, L.M.; Iwanicki, M.P.; Elias, K.M.; Karst, A.; Piao, H.; Ince, T.A.; Drage, M.G.; Dering, J.; Konecny, G.E. et al. Mesenchymal gene program-expressing ovarian cancer spheroids exhibit enhanced mesothelial clearance. J. Clin. Investig. 2014, 124, 2611–2625. [CrossRef] [PubMed]
88. Clark, R.; Krishnan, V.; Schoof, M.; Rodriguez, I.; Theriault, B.; Chekmareva, M.; Rinker-Schaeffer, C. Milky spots promote ovarian cancer metastatic colonization of peritoneal adipose in experimental models. Am. J. Pathol. 2013, 183, 576–591. [CrossRef] [PubMed]
89. Sodek, K.L.; Murphy, K.J.; Brown, T.J.; Ringuette, M.J. Cell-cell and cell-matrix dynamics in intraperitoneal cancer metastasis. Cancer Metastasis Rev. 2012, 31, 397–414. [CrossRef] [PubMed]
90. De Vlieghere, E.; Gremonprez, F.; Verset, L.; Marien, L.; Jones, C.J.; de Craene, B.; Berx, G.; Descamps, B.; Vanhove, C.; Remon, J.P. et al. Tumor-environment biomimetics delay peritoneal metastasis formation by deceiving and redirecting disseminated cancer cells. Biomaterials 2015, 54, 148–157. [CrossRef] [PubMed]
91. Ziprin, P.; Ridgway, P.F.; Pfistermuller, K.L.; Peck, D.H.; Darzi, A.W. ICAM-1 mediated tumor-mesothelial cell adhesion is modulated by IL-6 and TNF-alpha: A potential mechanism by which surgical trauma increases peritoneal metastases. Cell Commun. Adhes. 2003, 10, 141–154. [CrossRef] [PubMed]
92. Rump, A.; Morikawa, Y.; Tanaka, M.; Minami, S.; Umesaki, N.; Takeuchi, M.; Miyajima, A. Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion. J. Biol. Chem. 2004, 279, 9190–9198. [CrossRef]
93. Alkhamesi, N.A.; Ziprin, P.; Pfistermuller, K.; Peck, D.H.; Darzi, A.W. ICAM-1 mediated peritoneal carcinomatosis, a target for therapeutic intervention. Clin. Exp. Metastasis 2005, 22, 449–459. [CrossRef] [PubMed]
94. Casey, R.C.; Skubitz, A.P. CD44 and beta1 integrins mediate ovarian carcinoma cell migration toward extracellular matrix proteins. Clin. Exp. Metastasis 2000, 18, 67–75. [CrossRef] [PubMed]
95. Ksiazek, K.; Mikula-Pietrasik, J.; Catar, R.; Dworacki, G.; Winckiewicz, M.; Frydrychowicz, M.; Dragun, D.; Staniszewski, R.; Jorres, A.; Witowski, J. Oxidative stress-dependent increase in ICAM-1 expression promotes adhesion of colorectal and pancreatic cancers to the senescent peritoneal mesothelium. Int. J. Cancer 2010, 127, 293–303. [CrossRef] [PubMed]
96. Yu, G.; Tang, B.; Yu, P.W.; Peng, Z.H.; Qian, F.; Sun, G. Systemic and peritoneal inflammatory response after laparoscopic-assisted gastrectomy and the effect of inflammatory cytokines on adhesion of gastric cancer cells to peritoneal mesothelial cells. Surg. Endosc. 2010, 24, 2860–2870. [CrossRef]
97. Wagner, B.J.; Lob, S.; Lindau, D.; Horzer, H.; Guckel, B.; Klein, G.; Glatzle, J.; Rammensee, H.G.; Brucher, B.L.; Konigsrainer, A. Simvastatin reduces tumor cell adhesion to human peritoneal mesothelial cells by decreased expression of VCAM-1 and beta1 integrin. Int. J. Oncol. 2011, 39, 1593–1600. [PubMed]
98. Chen, C.N.; Chang, C.C.; Lai, H.S.; Jeng, Y.M.; Chen, C.I.; Chang, K.J.; Lee, P.H.; Lee, H. Connective tissue growth factor inhibits gastric cancer peritoneal metastasis by blocking integrin alpha3beta1-dependent adhesion. Gastric Cancer 2015, 18, 504–515. [CrossRef] [PubMed]
99. Jiang, C.-G.; Lv, L.; Liu, F.-R.; Wang, Z.-N.; Na, D.; Li, F.; Li, J.-B.; Sun, Z.; Xu, H.-M. Connective tissue growth factor is a positive regulator of epithelial-mesenchymal transition and promotes the adhesion with gastric cancer cells in human peritoneal mesothelial cells. Cytokine 2013, 61, 173–180. [CrossRef] [PubMed]
100. Kenny, H.A.; Lengyel, E. MMP-2 functions as an early response protein in ovarian cancer metastasis. Cell Cycle 2009, 8, 683–688. [CrossRef] [PubMed]
101. Kenny, H.A.; Kaur, S.; Coussens, L.M.; Lengyel, E. The initial steps of ovarian cancer cell metastasis are mediated by MMP-2 cleavage of vitronectin and fibronectin. J. Clin. Investig. 2008, 118, 1367–1379. [CrossRef] [PubMed]
102. Ranieri, D.; Raffa, S.; Parente, A.; Rossi Del Monte, S.; Ziparo, V.; Torrisi, M.R. High adhesion of tumor cells to mesothelial monolayers derived from peritoneal wash of disseminated gastrointestinal cancers. PLoS ONE 2013, 8, e57659. [CrossRef] [PubMed]
103. Slack-Davis, J.K.; Atkins, K.A.; Harrer, C.; Hershey, E.D.; Conaway, M. Vascular cell adhesion molecule-1 is a regulator of ovarian cancer peritoneal metastasis. Cancer Res. 2009, 69, 1469–1476. [CrossRef] [PubMed]
104. Kenny, H.A.; Chiang, C.-Y.; White, E.A.; Schryver, E.M.; Habis, M.; Romero, I.L.; Ladanyi, A.; Penicka, C.V.; George, J.; Matlin, K. et al. Mesothelial cells promote early ovarian cancer metastasis through fibronectin secretion. J. Clin. Investig. 2014, 124, 4614–4628. [CrossRef] [PubMed]
105. Strippoli, R.; Benedicto, I.; Pérez-Lozano, M.L.; Pellinen, T.; Sandoval, P.; López-Cabrera, M.; del Pozo, M.A. Inhibition of transforming growth factor-activated kinase 1 (TAK1) blocks and reverses epithelial to mesenchymal transition of mesothelial cells. PLoS ONE 2012, 7, e31492. [CrossRef] [PubMed]
106. Satoyoshi, R.; Kuriyama, S.; Aiba, N.; Yashiro, M.; Tanaka, M. Asporin activates coordinated invasion of scirrhous gastric cancer and cancer-associated fibroblasts. Oncogene 2015, 34, 650–660. [CrossRef] [PubMed]
107. Satoyoshi, R.; Aiba, N.; Yanagihara, K.; Yashiro, M.; Tanaka, M. Tks5 activation in mesothelial cells creates invasion front of peritoneal carcinomatosis. Oncogene 2015, 34, 3176–3187. [CrossRef] [PubMed]
108. Kenny, H.A.; Krausz, T.; Yamada, S.D.; Lengyel, E. Use of a novel 3D culture model to elucidate the role of mesothelial cells, fibroblasts and extra-cellular matrices on adhesion and invasion of ovarian cancer cells to the omentum. Int. J. Cancer 2007, 121, 1463–1472. [CrossRef] [PubMed]
109. Cai, J.; Tang, H.; Xu, L.; Wang, X.; Yang, C.; Ruan, S.; Guo, J.; Hu, S.; Wang, Z. Fibroblasts in omentum activated by tumor cells promote ovarian cancer growth, adhesion and invasiveness. Carcinogenesis 2011, 33, 20–29. [CrossRef] [PubMed]
110. Mikula-Pietrasik, J.; Sosinska, P.; Kucinska, M.; Murias, M.; Maksin, K.; Malinska, A.; Ziolkowska, A.; Piotrowska, H.; Wozniak, A.; Ksiazek, K. Peritoneal mesothelium promotes the progression of ovarian cancer cells in vitro and in a mice xenograft model in vivo. Cancer Lett. 2014, 355, 310–315. [CrossRef] [PubMed]
111. Tsukada, T.; Fushida, S.; Harada, S.; Yagi, Y.; Kinoshita, J.; Oyama, K.; Tajima, H.; Fujita, H.; Ninomiya, I.; Fujimura, T. et al. The role of human peritoneal mesothelial cells in the fibrosis and progression of gastric cancer. Int. J. Oncol. 2012, 41, 476–482. [CrossRef] [PubMed]
112. Schropfer, A.; Kammerer, U.; Kapp, M.; Dietl, J.; Feix, S.; Anacker, J. Expression pattern of matrix metalloproteinases in human gynecological cancer cell lines. BMC Cancer 2010, 10, 553. [CrossRef] [PubMed]
113. John, A.; Tuszynski, G. The role of matrix metalloproteinases in tumor angiogenesis and tumor metastasis. Pathol. Oncol. Res. 2001, 7, 14–23. [CrossRef] [PubMed]
114. Kessenbrock, K.; Plaks, V.; Werb, Z. Matrix metalloproteinases: Regulators of the tumor microenvironment. Cell 2010, 141, 52–67. [CrossRef] [PubMed]
115. Al-Alem, L.; Curry, T.E.J. Ovarian cancer: Involvement of the matrix metalloproteinases. Reproduction 2015, 150, R55–R64. [CrossRef] [PubMed]
116. Paulsson, J.; Micke, P. Prognostic relevance of cancer-associated fibroblasts in human cancer. Semin. Cancer Biol. 2014, 25, 61–68. [CrossRef] [PubMed]
117. Taddei, M.L.; Giannoni, E.; Comito, G.; Chiarugi, P. Microenvironment and tumor cell plasticity: An easy way out. Cancer Lett. 2013, 341, 80–96. [CrossRef] [PubMed]
118. Margetts, P.J.; Bonniaud, P.; Liu, L.; Hoff, C.M.; Holmes, C.J.; West-Mays, J.A.; Kelly, M.M. Transient overexpression of TGF-b1 induces epithelial mesenchymal transition in the rodent peritoneum. J. Am. Soc. Nephrol. 2005, 16, 425–436. [CrossRef] [PubMed]
119. Zhu, Z.; Yao, J.; Wang, F.; Xu, Q. TNF-alpha and the phenotypic transformation of human peritoneal mesothelial cell. Chin. Med. J. 2002, 115, 513–517. [PubMed]
120. Yu, Q.; Stamenkovic, I. Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. Genes Dev. 2000, 14, 163–176. [PubMed]
121. Belotti, D.; Calcagno, C.; Garofalo, A.; Caronia, D.; Riccardi, E.; Giavazzi, R.; Taraboletti, G. Vascular endothelial growth factor stimulates organ-specific host matrix metalloproteinase-9 expression and ovarian cancer invasion. Mol. Cancer Res. 2008, 6, 525–534. [CrossRef] [PubMed]
122. Birkedal-Hansen, H.; Moore, W.G.; Bodden, M.K.; Windsor, L.J.; Birkedal-Hansen, B.; DeCarlo, A.; Engler, J.A. Matrix metalloproteinases: A review. Crit. Rev. Oral Biol. Med. 1993, 4, 197–250. [PubMed]
123. Lee, I.K.; Vansaun, M.N.; Shim, J.H.; Matrisian, L.M.; Gorden, D.L. Increased metastases are associated with inflammation and matrix metalloproteinase-9 activity at incision sites in a murine model of peritoneal dissemination of colorectal cancer. J. Surg. Res. 2013, 180, 252–259. [CrossRef] [PubMed]
124. Lee, M.A.; Park, J.H.; Rhyu, S.Y.; Oh, S.T.; Kang, W.K.; Kim, H.N. Wnt3a expression is associated with MMP-9 expression in primary tumor and metastatic site in recurrent or stage IV colorectal cancer. BMC Cancer 2014, 14, 125. [CrossRef] [PubMed]
125. Liotta, L.A.; Kohn, E.C. The microenvironment of the tumor-host interface. Nature 2001, 411, 375–379. [CrossRef] [PubMed]
126. Kitadai, Y. Cancer-stromal cell interaction and tumor angiogenesis in gastric cancer. Cancer Microenviron. 2010, 3, 109–116. [CrossRef] [PubMed]
127. Winiarski, B.K.; Cope, N.; Alexander, M.; Pilling, L.C.; Warren, S.; Acheson, N.; Gutowski, N.J.; Whatmore, J.L. Clinical relevance of increased endothelial and mesothelial expression of proangiogenic proteases and VEGFA in the omentum of patients with metastatic ovarian high-grade serous carcinoma. Transl. Oncol. 2014, 7, 267–276. e4. [CrossRef] [PubMed]
128. Pérez-Lozano, M.L.; Sandoval, P.; Rynne-Vidal, A.; Aguilera, A.; Jiménez-Heffernan, J.A.; Albar-Vizcaíno, P.; Majano, P.L.; Sánchez-Tomero, J.A.; Selgas, R.; López-Cabrera, M. Functional relevance of the switch of VEGF receptors/co-receptors during peritoneal dialysis-induced mesothelial to mesenchymal transition. PLoS ONE 2013, 8, e60776. [CrossRef] [PubMed]
129. Aroeira, L.S.; Aguilera, A.; Selgas, R.; Ramirez-Huesca, M.; Perez Lozano, M.L.; Cirugeda, A.; Bajo, M.A.; del Peso, G.; Sanchez-Tomero, J.A.; Jimenez-Heffernan, J.A. et al. Mesenchymal conversion of mesothelial cells as a mechanism responsible for high solute transport rate in peritoneal dialysis: Role of vascular endothelial growth factor. Am. J. Kidney Dis. 2005, 46, 938–948. [CrossRef] [PubMed]
130. Sako, A.; Kitayama, J.; Yamaguchi, H.; Kaisaki, S.; Suzuki, H.; Fukatsu, K.; Fujii, S.; Nagawa, H. Vascular endothelial growth factor synthesis by human omental mesothelial cells is augmented by fibroblast growth factor-2: Possible role of mesothelial cell on the development of peritoneal metastasis. J. Surg. Res. 2003, 115, 113–120. [CrossRef]
131. Sako, A.; Kitayama, J.; Koyama, H.; Ueno, H.; Uchida, H.; Hamada, H.; Nagawa, H. Transduction of soluble Flt-1 gene to peritoneal mesothelial cells can effectively suppress peritoneal metastasis of gastric cancer. Cancer Res. 2004, 64, 3624–3628. [CrossRef]
132. Micke, P.; Ostman, A. Exploring the tumor environment: Cancer-associated fibroblasts as targets in cancer therapy. Expert Opin. Ther. Targets 2005, 9, 1217–1233. [CrossRef] [PubMed]
133. Yoshimura, A.; Wakabayashi, Y.; Mori, T. Cellular and molecular basis for the regulation of inflammation by TGF-beta. J. Biochem. 2010, 147, 781–792. [CrossRef] [PubMed]
134. Wang, X.; Nie, J.; Jia, Z.; Feng, M.; Zheng, Z.; Chen, W.; Li, X.; Peng, W.; Zhang, S.; Sun, L. et al. Impaired TGF-beta signalling enhances peritoneal inflammation induced by E. coli in rats. Nephrol. Dial. Transplant. 2010, 25, 399–412. [CrossRef] [PubMed]
135. Loureiro, J.; Schilte, M.; Aguilera, A.; Albar-Vizcaino, P.; Ramirez-Huesca, M.; Perez Lozano, M.L.; Gonzalez-Mateo, G.; Aroeira, L.S.; Selgas, R.; Mendoza, L. et al. BMP-7 blocks mesenchymal conversion of mesothelial cells and prevents peritoneal damage induced by dialysis fluid exposure. Nephrol. Dial. Transpl. 2010, 25, 1098–1108. [CrossRef] [PubMed]
136. Vargha, R.; Endemann, M.; Kratochwill, K.; Riesenhuber, A.; Wick, N.; Krachler, A.-M.; Malaga-Dieguez, L.; Aufricht, C. Ex vivo reversal of in vivo transdifferentiation in mesothelial cells grown from peritoneal dialysate effluents. Nephrol. Dial. Transplant. 2006, 21, 2943–2947. [CrossRef] [PubMed]
137. Strippoli, R.; Benedicto, I.; Lozano, M.L.P.; Cerezo, A.; López-Cabrera, M.; del Pozo, M.A. Epithelial-to-mesenchymal transition of peritoneal mesothelial cells is regulated by an ERK/NF-_B/Snail1 pathway. Dis. Model Mech. 2008, 1, 264–274. [CrossRef] [PubMed]
138. Strippoli, R.; Benedicto, I.; Foronda, M.; Pérez-Lozano, M.L.; Sánchez-Perales, S.; López-Cabrera, M.; del Pozo, M.A. p38 maintains E-cadherin expression by modulating TAK1-NF-kappa B during epithelial-to-mesenchymal transition. J. Cell Sci. 2010, 123, 4321–4331. [CrossRef] [PubMed]
139. Jang, Y.-H.; Shin, H.-S.; Choi, H.S.; Ryu, E.-S.; Kim, M.J.; Min, S.K.; Lee, J.-H.; Lee, H.K.; Kim, K.-H.; Kang, D.-H. Effects of dexamethasone on the TGF-b1-induced epithelial-to-mesenchymal transition in human peritoneal mesothelial cells. Lab. Investig. 2012, 93, 194–206. [CrossRef] [PubMed]
140. Aroeira, L.S.; Lara-Pezzi, E.; Loureiro, J.; Aguilera, A.; Ramírez-Huesca, M.; González-Mateo, G.; Pérez-Lozano, M.L.; Albar-Vizcaíno, P.; Bajo, M.-A.; del Peso, G. et al. Cyclooxygenase-2 mediates dialysate-induced alterations of the peritoneal membrane. J. Am. Soc. Nephrol. 2009, 20, 582–592. [CrossRef] [PubMed]
141. Fabbrini, P.; Schilte, M.N.; Zareie, M.; ter Wee, P.M.; Keuning, E.D.; Beelen, R.H.J.; van den Born, J. Celecoxib treatment reduces peritoneal fibrosis and angiogenesis and prevents ultrafiltration failure in experimental peritoneal dialysis. Nephrol. Dial. Transpl. 2009, 24, 3669–3676. [CrossRef] [PubMed]
142. Menczer, J. Cox-2 expression in ovarian malignancies: A review of the clinical aspects. Eur. J. Obstet. Gynecol. Reprod. Biol. 2009, 146, 129–132. [CrossRef] [PubMed]
143. Rizzo, M.T. Cyclooxygenase-2 in oncogenesis. Clin. Chim. Acta 2011, 412, 671–687. [CrossRef] [PubMed]
144. Arber, N.; Eagle, C.J.; Spicak, J.; Rácz, I.; Dite, P.; Hajer, J.; Zavoral, M.; Lechuga, M.J.; Gerletti, P.; Tang, J. et al. PreSAP Trial Investigators Celecoxib for the prevention of colorectal adenomatous polyps. N. Engl. J. Med. 2006, 355, 885–895. [CrossRef] [PubMed]
145. Baron, J.A.; Sandler, R.S.; Bresalier, R.S.; Quan, H.; Riddell, R.; Lanas, A.; Bolognese, J.A.; Oxenius, B.; Horgan, K.; Loftus, S. et al. APPROVe trial investigators a randomized trial of rofecoxib for the chemoprevention of colorectal adenomas. Gastroenterology 2006, 131, 1674–1682. [CrossRef] [PubMed]
146. Midgley, R.S.; McConkey, C.C.; Johnstone, E.C.; Dunn, J.A.; Smith, J.L.; Grumett, S.A.; Julier, P.; Iveson, C.; Yanagisawa, Y.; Warren, B. et al. Phase III randomized trial assessing rofecoxib in the adjuvant setting of colorectal cancer: Final results of the VICTOR trial. J. Clin. Oncol. 2010, 28, 4575–4580. [CrossRef] [PubMed]
147. Solomon, S.D.; Pfeffer, M.A.; McMurray, J.J.V.; Fowler, R.; Finn, P.; Levin, B.; Eagle, C.; Hawk, E.; Lechuga, M.; Zauber, A.G. et al. APC and PreSAP Trial Investigators Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas. Circulation 2006, 114, 1028–1035. [CrossRef] [PubMed]
148. Watanabe, T.; Hashimoto, T.; Sugino, T.; Soeda, S.; Nishiyama, H.; Morimura, Y.; Yamada, H.; Goodison, S.; Fujimori, K. Production of IL1-beta by ovarian cancer cells induces mesothelial cell beta1-integrin expression facilitating peritoneal dissemination. J. Ovarian Res. 2012, 5, 7. [CrossRef] [PubMed]
149. Yokoyama, Y.; Sedgewick, G.; Ramakrishnan, S. Endostatin binding to ovarian cancer cells inhibits peritoneal attachment and dissemination. Cancer Res. 2007, 67, 10813–10822. [CrossRef] [PubMed]
150. Mitra, A.K.; Sawada, K.; Tiwari, P.; Mui, K.; Gwin, K.; Lengyel, E. Ligand-independent activation of c-Met by fibronectin and _(5)_(1)-integrin regulates ovarian cancer invasion and metastasis. Oncogene 2011, 30, 1566–1576. [CrossRef] [PubMed]
151. Sawada, K.; Mitra, A.K.; Radjabi, A.R.; Bhaskar, V.; Kistner, E.O.; Tretiakova, M.; Jagadeeswaran, S.; Montag, A.; Becker, A.; Kenny, H.A. et al. Loss of E-cadherin promotes ovarian cancer metastasis via alpha 5-integrin, which is a therapeutic target. Cancer Res. 2008, 68, 2329–2339. [CrossRef] [PubMed]
152. Ksiazek, K.; Mikula-Pietrasik, J.; Korybalska, K.; Dworacki, G.; Jörres, A.; Witowski, J. Senescent peritoneal mesothelial cells promote ovarian cancer cell adhesion. Am. J. Pathol. 2009, 174, 1230–1240. [CrossRef] [PubMed]
153. Ksiazek, K. Mesothelial cell: A multifaceted model of aging. Ageing Res. Rev. 2013, 12, 595–604. [CrossRef] [PubMed]
154. Serkies, K.; Sinacki, M.; Jassem, J. The role of hormonal factors and endocrine therapy in ovarian cancer. Contemp. Oncol. (Pozn) 2013, 17, 14–19. [CrossRef] [PubMed]
155. Loureiro, J.; Sandoval, P.; del Peso, G.; González-Mateo, G.; Fernández-Millara, V.; Santamaria, B.; Bajo, M.A.; Sánchez-Tomero, J.A.; Guerra-Azcona, G.; Selgas, R. et al. Tamoxifen ameliorates peritoneal membrane damage by blocking mesothelial to mesenchymal transition in peritoneal dialysis. PLoS ONE 2013, 8, e61165. [CrossRef] [PubMed]
156. Mizutani, K.; Kofuji, K.; Shirouzu, K. The significance of MMP-1 and MMP-2 in peritoneal disseminated metastasis of gastric cancer. Surg. Today 2000, 30, 614–621. [CrossRef] [PubMed]
157. Cathcart, J.; Pulkoski-Gross, A.; Cao, J. Targeting matrix metalloproteinases in cancer: Bringing new life to old ideas. Genes Dis. 2015, 2, 26–34. [CrossRef] [PubMed]
158. Gialeli, C.; Theocharis, A.D.; Karamanos, N.K. Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting. FEBS J. 2010, 278, 16–27. [CrossRef] [PubMed]
159. Egeblad, M.; Werb, Z. New functions for the matrix metalloproteinases in cancer progression. Nat. Rev. Cancer 2002, 2, 161–174. [CrossRef] [PubMed]
160. Wu, Q.J.; Gong, C.Y.; Luo, S.T.; Zhang, D.M.; Zhang, S.; Shi, H.S.; Lu, L.; Yan, H.X.; He, S.S.; Li, D.D. et al. AAV-mediated human PEDF inhibits tumor growth and metastasis in murine colorectal peritoneal carcinomatosis model. BMC Cancer 2012, 12, 129. [CrossRef] [PubMed]
161. Masoumi Moghaddam, S.; Amini, A.; Morris, D.L.; Pourgholami, M.H. Significance of vascular endothelial growth factor in growth and peritoneal dissemination of ovarian cancer. Cancer Metastasis Rev. 2011, 31, 143–162. [CrossRef] [PubMed]
162. Gadducci, A.; Lanfredini, N.; Sergiampietri, C. Antiangiogenic agents in gynecological cancer: State of art and perspectives of clinical research. Crit. Rev. Oncol. Hematol. 2015. [CrossRef] [PubMed]
163. Mulder, K.; Scarfe, A.; Chua, N.; Spratlin, J. The role of bevacizumab in colorectal cancer: Understanding its benefits and limitations. Expert Opin. Biol. Ther. 2011, 11, 405–413. [CrossRef] [PubMed]
164. Perren, T.J.; Swart, A.M.; Pfisterer, J.; Ledermann, J.A.; Pujade-Lauraine, E.; Kristensen, G.; Carey, M.S.; Beale, P.; Cervantes, A.; Kurzeder, C. et al. A phase 3 trial of bevacizumab in ovarian cancer. N. Engl. J. Med. 2011, 365, 2484–2496. [CrossRef] [PubMed]